Table 1 Baseline clinical characteristics of the SU2C-MARK cohort

From: Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Patient characteristics (n = 393)

All patients, no. (%)

Age (years), median (range)

64 (29–90)

Sex

 Male

182 (46)

 Female

207 (53)

Smoking status

 Never

46 (12)

 Former

283 (72)

 Current

60 (15)

Smoking pack-years

 0

47 (12)

 1–10

46 (12)

 11–20

50 (13)

 21–40

125 (32)

 >40

113 (29)

Histology

 Adenocarcinoma

286 (73)

 Squamous

77 (20)

 LCNE

9 (2)

 Other

17 (4)

PD-L1 expression

 0%

56 (14)

 ≥1%

168 (43)

Prior lines of therapy

 0

143 (36)

 1

150 (38)

 ≥2

96 (24)

Therapy

 PD-(L)1 only

317 (81)

 PD-(L)1 + CTLA4

65 (17)

 PD-(L)1 + chemotherapy

2 (1)

BOR

 CR/PR

142 (36)

 SD

110 (28)

 PD

132 (33)

  1. The SU2C-MARK cohort consists of 393 patients with NSCLC treated with immune checkpoint blockade therapy in the advanced setting. BOR to the first line containing a PD-(L)1 agent was recorded.
Back to article page